Back to School: How biopharma can reboot drug development. Access exclusive analysis here
CytomX partnered with Pfizer to develop and commercialize multiple Probody-drug conjugates (PDCs) in undisclosed cancer indications.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury